Philadelphia recently ranked as one of the top markets in the US for life sciences, with continuous growth and USD 4bn in new construction that supports the industry's expansion.
Through PABC's existing campus and the new B+Labs incubator, PABC serves a critical need in the region for incubator space that includes the same state-of-the-art technologies that are accelerating drug discovery in other major cities.
As a founding sponsor of B+Labs, which is a partnership between the PABC and Brandywine Realty Trust, Thermo Fisher will provide its advanced technology and expertise to emerging biotech residents.
Evrys Bio has been at the PABC for 10 years. The company's president and CEO, Lillian W. Chiang, PhD, MBA, has started companies at two other incubators and says the PABC is superior.
Data show that early stage biotechs are more successful at raising series A funding, securing larger deal sizes and achieving success when they are part of an incubator ecosystem. The PABC, with expertise from the Blumberg Institute, is one of the nation's most successful life science incubators.
Pennsylvania Biotechnology Center is a nonprofit life sciences incubator-accelerator, offering state-of-the-art laboratory and office space to early-stage biotech companies, as well as the Hepatitis B Foundation and Blumberg Institute.
Managed by the Institute and led by a board appointed by the Foundation, PABC is home to more than 40 small to mid-size science, research and pharmaceutical companies.
The center uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries that will make a difference.
PABC is near Doylestown in Bucks County, in the heart of the Philadelphia-New Jersey pharma belt.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients